BIOTECHNOLOGY

New Data Show Genentech’s Subcutaneously Administered Crovalimab Achieved Disease Control and Was Well-Tolerated in People With Paroxysmal Nocturnal Hemoglobinuria (PNH)

“With the option for subcutaneous self-administration, crovalimab could help meet [...]

By |2023-06-09T14:47:25+00:00June 9, 2023|3rd Party Medical Device Industry News|Comments Off on New Data Show Genentech’s Subcutaneously Administered Crovalimab Achieved Disease Control and Was Well-Tolerated in People With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Read More

Innovent Updates Phase 1b Data of IBI939 (Anti-TIGIT Monoclonal Antibody) Combined with Sintilimab in Previously Untreated PD-L1-selected NSCLC at the 2023 ASCO Annual Meeting

The company updated the Phase 1b efficacy and safety results [...]

By |2023-06-04T19:18:10+00:00June 4, 2023|3rd Party Medical Device Industry News|Comments Off on Innovent Updates Phase 1b Data of IBI939 (Anti-TIGIT Monoclonal Antibody) Combined with Sintilimab in Previously Untreated PD-L1-selected NSCLC at the 2023 ASCO Annual Meeting
Read More

Pangaea Data Awarded Strategic Partnership by Mersey Care NHS Foundation Trust and the University of Liverpool’s Mental Health Research for Innovation Centre (M-RIC)

Dr. Vibhor Gupta, Founder and Director at Pangaea, said: “We [...]

By |2023-06-01T17:56:24+00:00June 1, 2023|3rd Party Medical Device Industry News|Comments Off on Pangaea Data Awarded Strategic Partnership by Mersey Care NHS Foundation Trust and the University of Liverpool’s Mental Health Research for Innovation Centre (M-RIC)
Read More

DISCLAIMER

JOIN OUR MAILING LIST

© YOUNG & PARTNERS LLC   |   535 Fifth Avenue, 4th Floor, New York, New York 10017 | 212-682-5555

Go to Top